Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
A deal between the microbiome specialist Microbiotica and Roche’s Genentech division has raised hopes in the sector again.
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.